Future research should explore differences in the strength of association among the three types of biomarkers of Alzheimer’s disease (i.e., amyloid, tau, and neurodegeneration) with episodic memory and semantic impairment for timely identification of individuals at high risk for clinical dementia. The gene discussed is MAPT; the disease is dementia.